Fulgent Genetics Inc
$ 19.14
3.18%
07 Aug - close price
- Market Cap 526,643,000 USD
- Current Price $ 19.14
- High / Low $ 19.22 / 18.48
- Stock P/E N/A
- Book Value 36.40
- EPS -2.83
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.08 %
- 52 Week High 31.04
- 52 Week Low 13.46
About
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Analyst Target Price
$19.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-01 | 2026-02-27 | 2025-11-07 | 2025-08-01 | 2025-05-02 | 2025-02-28 | 2024-11-08 | 2024-08-02 | 2024-05-03 | 2024-02-28 | 2023-11-03 |
| Reported EPS | -0.88 | -0.36 | 0.16 | 0.14 | 0.07 | 0.04 | 0.04 | 0.31 | 0.15 | -0.01 | 0.28 | -0.39 |
| Estimated EPS | -0.79 | -0.35 | -0.0602 | -0.22 | -0.18 | -0.18 | -0.369 | -0.15 | -0.3 | -0.32 | -0.29 | -0.32 |
| Surprise | -0.09 | -0.01 | 0.2202 | 0.36 | 0.25 | 0.22 | 0.409 | 0.46 | 0.45 | 0.31 | 0.57 | -0.07 |
| Surprise Percentage | -11.3924% | -2.8571% | 365.7807% | 163.6364% | 138.8889% | 122.2222% | 110.8401% | 306.6667% | 150% | 96.875% | 196.5517% | -21.875% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FLGT
2026-08-08 05:40:58
Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "hold" with a $27.50 price target. This downgrade follows Fulgent's recent quarterly earnings report, which missed analyst expectations for both EPS and revenue. Insiders have sold a significant number of shares, though some institutional investors have increased their holdings.
2026-08-07 23:40:58
This article presents the slide deck published by Fulgent Genetics, Inc. in conjunction with their Q2 2026 earnings call. The content is provided by Seeking Alpha's transcripts team, which publishes numerous quarterly earnings calls. The aim is to share transcript-related developments with readers.
2026-08-07 14:40:58
This article provides a comprehensive overview of Fulgent Genetics, Inc. (FLGT), including its stock price, historical data, company profile, and financial performance. As of August 7, the stock closed at $19.14, up 3.18%. The company specializes in clinical diagnostic and therapeutic development solutions, offering a range of genetic and oncology tests, and is headquartered in El Monte, California.
2026-08-07 14:40:58
This article provides a detailed overview of Fulgent Genetics, Inc. (FLGT), including its current stock price, recent performance metrics, and key financial data. It also outlines the company's diagnostic and therapeutic solutions, target markets, and analyst ratings, alongside comparisons with similar companies in the healthcare sector.
2026-08-04 21:13:35
Piper Sandler has increased its target price for FULGENT GENETICS INC (FLGT.O) to $19.00, up from the previous $15.00. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The article briefly reports this change in target price.
2026-08-04 03:23:00
Piper Sandler has raised its target price for Fulgent Genetics Inc (FLGT.O) shares to $19.00 from $15.00. This update indicates a more optimistic outlook from the analyst firm regarding the company's future stock performance. The report was issued by Reuters on August 4, 2026.
